ClinicalTrials.gg
CompletedNCT01310231Updated Apr 14, 2021Results posted

A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer

A Phase 2 interventional study of Metformin and Placebo in Metastatic Breast Cancer, sponsored by Ozmosis Research Inc.. Completed at 5 sites in Canada. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by Ozmosis Research Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 41 studies testing metformin in Breast Neoplasms — 1 open to participants now, 1 under way, 1 of them phase 3. Metformin · Breast Neoplasms.

Enrollment
24th of 41
40 · median 49
Started
2011
with 4 others
Phase 2
27 of 41
none open now
Registered
8th of 41
by date

Among the 41 studies testing metformin in Breast Neoplasms, this one is the 24th largest by enrollment, is one of 5 that started in 2011, is one of 27 in phase 2, and was the 8th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 41 studies testing metformin in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing metformin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the addition of metformin to standard chemotherapy improves progression free survival in women with metastatic breast cancer.

Read the detailed description

A double blind Phase II randomized study of metformin versus (vs) placebo in non-diabetic women on first to fourth line chemotherapy with anthracycline, taxane, platinum, capecitabine or vinorelbine based regimens for metastatic or unresectable locally advanced breast cancer (BC). Patients were randomized to receive metformin 850 mg tablets or placebo once daily for two days as ramp-up, followed by one tablet twice a day for the duration of the study. Randomization was stratified by line of chemotherapy (1st, 2nd, 3rd and 4th line) and hormone receptor status (ER and/or PgR positive versus both negative). All patients were required to have measureable or non-measureable, but evaluable metastases at study entry. Metformin or placebo was to be continued until disease progression, even if chemotherapy was changed or stopped prior to disease progression. Recruitment took place at five sites in Ontario, Canada: Mount Sinai Hospital, Princess Margaret Cancer Centre, St. Michael's Hospital, Toronto and London Regional Cancer Centre, London.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Metastatic Breast Cancer
  • Metformin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven invasive breast cancer with spread outside of breast, ipsilateral axillary and supraclavicular nodal areas (Histological confirmation of metastases is not required) OR, Locally advanced breast cancer that is to initial anticancer treatment.
  • A decision has been made to administer single or multiple agent first or chemotherapy that includes one of the following agents: anthracycline, taxane, platinum, capecitabine.
  • Age: 18 to 75 years at the time of registration
  • Invasive breast cancer, any ER or PgR status
  • performance status 0-2
  • of at least 6 months
  • Adequate hepatic and renal function ( and ALT \< 1.8 X for the institution, alkaline phosphatase ≤ 2X upper limit of normal for the institution, within normal limits for the institution (expect in patients with Gilbert's syndrome who will be eligible regardless of bilirubin) and creatinine ≤ 130 umol/L)
  • Blood counts: Neutrophils must be at least 1,000/mm3 and ≥ 75,000/mm3.
  • Ability to understand and to provide written for the study
  • Absence of any psychological, familial, sociological, or other patient related factors that might preclude compliance with the study protocol
  • Measurable or non measurable (but evaluable) tumour must be present - radiologic or clinical evaluation must have been performed within 4 weeks prior to registration.

Exclusion criteria

Exclusion Criteria:

  • More than one previous line(s) of chemotherapy for disease - if prior chemotherapy has been administered, the last date of treatment must have been given at least 3 weeks prior to registration [any systemic treatment is acceptable]
  • If prior hormone therapy (as adjuvant or metastatic therapy) has been administered, it must have been stopped at least 3 weeks prior to registration
  • Radiotherapy to a target or non target lesion within 4 weeks of registration
  • Known
  • History of cardiac failure
  • Known or allergy to metformin
  • History of or known diabetes or baseline fasting glucose ≥ 7.0 mmol/L
  • History of lactic or other metabolic acidosis
  • Use of metformin within 3 months of registration
  • Current or planned pregnancy or lactation in women of . Patients of childbearing potential must have a negative serum pregnancy test.
  • Fertile patients must agree to use an effective method of while on study treatment; which could include IUD, condoms or other barrier methods of birth control
  • Habitual alcohol intake of more than three drinks daily
  • Concurrent use of any biguanide medication (other than metformin as a study medication)
  • Patients with ≥ grade 2 diarrhea at baseline, malabsorption syndrome or unable to swallow oral medication
  • Previous or concurrent , except non-melanoma skin cancers, unless curatively treated and with no evidence of recurrence for ≥ 5 years.
  • Use of any agent within 28 days prior to registration.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Metformin

    Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).

    Drug: Metformin

  • Placebo comparator
    Placebo

    Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).

    Drug: Placebo

Interventions

  • metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line). Number of cycles: Until progression or unacceptable toxicity develops.

  • DrugPlacebo

    Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line). Number of cycles: until progression or unacceptable toxicity develops.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival.

    Scans will be repeated every 9 weeks. Local follow up for survival will continue until all patients have died or for a maximum total follow up of 3 years, which ever occurs first. The two study arms will be compared in an intent to treat fashion using Cox proportional hazard analysis, with the stratification variables included in the model. Treatment discontinuation for toxicity or other reasons will be considered an event.

    Time frame: From date of randomization to first documented progression or death, which ever occurs first, assessed up to 3 years.

Secondary outcomes

  1. Overall Response Rate

    Overall response rate in patients with measureable disease based upon RECIST Version 1.1. Patients will have scans repeated every 9 weeks and overall review of response across the study will be done every 6 months. The overall response rate is defined as number of patients with a best overall response of CR or PR, as a proportion of all patient with measurable disease at baseline. The response rate between arms will be compared using logistic regression with treatment as factor, adjusted for strata.

    Time frame: From baseline until time of best response, assessed up to 3 years

  2. Number of Participants With Grade 1 or 2 Adverse Events

    Adverse events graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Lower grade (grade 1 and 2) and higher grade (grade 3 and 4) are presented separately. A detailed breakdown of adverse events are given in the Adverse Events section

    Time frame: Up to 30 days after end of study

  3. Number of Participants With Grade 3 or 4 Adverse Events

    Adverse events graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Lower grade (grade 1 and 2) and higher grade (grade 3 and 4) are presented separately. A detailed breakdown of adverse events are given in the Adverse Events section

    Time frame: Up to 30 days after end of study

  4. EORTC Quality of Life Measures

    European Organization for Research and Treatment of Cancer (EORTC) quality of life measures: global health status and 5 functioning scales. Baseline and Cycle 2 outcomes are scaled from 0 to 100; higher scores indicate better functioning or better health status. CHANGE in these scales from baseline to cycle 2 is reported for each arm.

    Time frame: From baseline to cycle 2 of chemotherapy

  5. Change in Fasting Glucose (mmol/L)

    Change in fasting glucose from baseline to Cycle 2

    Time frame: Baseline to Cycle 2

  6. Change in Fasting Insulin

    Change in fasting insulin from baseline to Cycle 2

    Time frame: Baseline to Cycle 2

  7. Change in Insulin Resistance From Baseline to Cycle 2 Measured Using Homeostatic Model Assessment (HOMA-IR)

    HOMA-IR is an index calculated from fasting insulin (pmol/L) and glucose (mmol/L) as insulin/6.9 times glucose/22.5.

    Time frame: Baseline to Cycle 2

  8. Immunohistochemical Predictors of Metformin Benefit and to Explore Changes in These Variables in Women Who Undergo Serial Biopsies of Their Metastases.

    Immunohistochemical analysis of different markers (IR, LKB1, phosphorylated AKT, S6K, ribosomal protein S6, 4E-BP1, and stathmin) pre and post first cycle of chemotherapy with metformin as well as in the original tumour tissue. Change in the phospho-markers of PI3K/mTOR will be summarized before and after the first cycle of chemotherapy with a focus on detection between the study arms.

    Time frame: Baseline and 3 weeks.

  9. Gene Expression Predictors of Potential Metformin Benefit Including Exploration of Changes in These Variables in Women Who Undergo Serial Biopsies of Their Metastases

    Gene expression profiles in the baseline (original tumour) and, when available, pre and post cycle 1 chemotherapy will be established and change in gene signature pre and post chemotherapy will be explored.

    Time frame: Baseline and 4 weeks

07

Results

Posted Apr 14, 2021
Limitations and caveats
Limitations include relatively small sample size, with associated imbalances in frequency of visceral (vs nonvisceral) metastatic disease, in HER2 positive and negative cancers, and in type of chemotherapy received in the metformin vs placebo arms.

Participant flow

Participant flow — Overall Study
MilestoneMetforminPlacebo
Started2218
Received intervention2217
Discontinued intervention01
Analyzed for survival2218
Analyzed for response, toxicity, qol2217
Completed2217
Not completed01

Outcome measures

PrimaryProgression Free Survival.

Scans will be repeated every 9 weeks. Local follow up for survival will continue until all patients have died or for a maximum total follow up of 3 years, which ever occurs first. The two study arms will be compared in an intent to treat fashion using Cox proportional hazard analysis, with the stratification variables included in the model. Treatment discontinuation for toxicity or other reasons will be considered an event.

Time frame:
From date of randomization to first documented progression or death, which ever occurs first, assessed up to 3 years.
Reported as:
Mean · months
Progression Free Survival.
monthsMetforminPlacebo
Progression Free Survival.5.4 ± 1.046.3 ± 1.68
Statistical analysis
  • Metformin vs Placebo · Regression, Cox · p = 0.71 (One-sided p-value for group-effect obtained from Cox model. The prespecified threshold was 0.20 (one-sided).) · Hazard ratio (hr): 1.2 · 95% CI 0.63 to 2.31Ratio of hazard of progression in the Metformin group relative to hazard in the Placebo group
SecondaryOverall Response Rate

Overall response rate in patients with measureable disease based upon RECIST Version 1.1. Patients will have scans repeated every 9 weeks and overall review of response across the study will be done every 6 months. The overall response rate is defined as number of patients with a best overall response of CR or PR, as a proportion of all patient with measurable disease at baseline. The response rate between arms will be compared using logistic regression with treatment as factor, adjusted for strata.

Time frame:
From baseline until time of best response, assessed up to 3 years
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsMetforminPlacebo
Clinical benefit127
Progressive disease109
Statistical analysis
  • Metformin vs Placebo · Regression, Logistic · p = 0.41 (Two-side p-value from a logistic regression model.) · Odds ratio (or): 1.77 · 95% CI 0.45 to 6.99Logistic regression model included metf/plac and the two stratification variables line of chemotherapy and hormone receptor status.
SecondaryNumber of Participants With Grade 1 or 2 Adverse Events

Adverse events graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Lower grade (grade 1 and 2) and higher grade (grade 3 and 4) are presented separately. A detailed breakdown of adverse events are given in the Adverse Events section

Time frame:
Up to 30 days after end of study
Reported as:
Count of participants · Participants
Number of Participants With Grade 1 or 2 Adverse Events
ParticipantsMetforminPlacebo
Number of Participants With Grade 1 or 2 Adverse Events156
SecondaryNumber of Participants With Grade 3 or 4 Adverse Events

Adverse events graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Lower grade (grade 1 and 2) and higher grade (grade 3 and 4) are presented separately. A detailed breakdown of adverse events are given in the Adverse Events section

Time frame:
Up to 30 days after end of study
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or 4 Adverse Events
ParticipantsMetforminPlacebo
Number of Participants With Grade 3 or 4 Adverse Events710
SecondaryEORTC Quality of Life Measures

European Organization for Research and Treatment of Cancer (EORTC) quality of life measures: global health status and 5 functioning scales. Baseline and Cycle 2 outcomes are scaled from 0 to 100; higher scores indicate better functioning or better health status. CHANGE in these scales from baseline to cycle 2 is reported for each arm.

Time frame:
From baseline to cycle 2 of chemotherapy
Reported as:
Mean · EORTC functioning scale
EORTC Quality of Life Measures
EORTC functioning scaleMetforminPlacebo
Global health Status-12.7 ± 18.76.3 ± 19.6
Physical functioning-6.0 ± 12.92.1 ± 12.1
Role functioning-18.4 ± 27.7-2.1 ± 20.1
Emotional functioning-2.6 ± 21.12.3 ± 16.7
Cognitive functioning-0.9 ± 10.40 ± 17.2
Social functioning-12.3 ± 29.84.2 ± 23.2
SecondaryChange in Fasting Glucose (mmol/L)

Change in fasting glucose from baseline to Cycle 2

Time frame:
Baseline to Cycle 2
Reported as:
Median · mmol/L
Change in Fasting Glucose (mmol/L)
mmol/LMetforminPlacebo
Change in Fasting Glucose (mmol/L)-0.2 (-0.4 to 0.3)0 (-0.15 to 0.25)
SecondaryChange in Fasting Insulin

Change in fasting insulin from baseline to Cycle 2

Time frame:
Baseline to Cycle 2
Reported as:
Median · pmol/L
Change in Fasting Insulin
pmol/LMetforminPlacebo
Change in Fasting Insulin-7 (-14.25 to 0.5)1 (-13.5 to 20.5)
SecondaryChange in Insulin Resistance From Baseline to Cycle 2 Measured Using Homeostatic Model Assessment (HOMA-IR)

HOMA-IR is an index calculated from fasting insulin (pmol/L) and glucose (mmol/L) as insulin/6.9 times glucose/22.5.

Time frame:
Baseline to Cycle 2
Reported as:
Median · HOMA-IR score
Change in Insulin Resistance From Baseline to Cycle 2 Measured Using Homeostatic Model Assessment (HOMA-IR)
HOMA-IR scoreMetforminPlacebo
Change in Insulin Resistance From Baseline to Cycle 2 Measured Using Homeostatic Model Assessment (HOMA-IR)-0.16 (-0.85 to 0)0.12 (-0.52 to 0.62)
SecondaryImmunohistochemical Predictors of Metformin Benefit and to Explore Changes in These Variables in Women Who Undergo Serial Biopsies of Their Metastases.

Immunohistochemical analysis of different markers (IR, LKB1, phosphorylated AKT, S6K, ribosomal protein S6, 4E-BP1, and stathmin) pre and post first cycle of chemotherapy with metformin as well as in the original tumour tissue. Change in the phospho-markers of PI3K/mTOR will be summarized before and after the first cycle of chemotherapy with a focus on detection between the study arms.

Time frame:
Baseline and 3 weeks.

No measurements were reported for this outcome.

SecondaryGene Expression Predictors of Potential Metformin Benefit Including Exploration of Changes in These Variables in Women Who Undergo Serial Biopsies of Their Metastases

Gene expression profiles in the baseline (original tumour) and, when available, pre and post cycle 1 chemotherapy will be established and change in gene signature pre and post chemotherapy will be explored.

Time frame:
Baseline and 4 weeks

No measurements were reported for this outcome.

Adverse events

Collected over The Adverse Events reporting period is defined as the time of consent signature until 30 days after date of off study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin19/22 (86.4%)3/22 (13.6%)22/22 (100%)
Placebo15/18 (83.3%)4/17 (23.5%)15/17 (88.2%)
Most frequent serious events
Most frequent serious events
EventMetforminPlacebo
febrile neutropenia with urinary tract infectionInfections and infestations0/221/17
hypoxiaRespiratory, thoracic and mediastinal disorders0/221/17
ascites with hyponatraemiaGastrointestinal disorders0/221/17
thromboembolismVascular disorders0/221/17
febrile neutropenia with respiratory infectionInfections and infestations1/220/17
urosepsisInfections and infestations1/220/17
dyspnoeaRespiratory, thoracic and mediastinal disorders1/220/17
Most frequent other events
Showing 10 of 102
Most frequent other events
EventMetforminPlacebo
DIARRHOEAGastrointestinal disorders16/227/17
NAUSEAGastrointestinal disorders12/2211/17
FATIGUEGeneral disorders11/227/17
CONSTIPATIONGastrointestinal disorders5/228/17
VOMITINGGastrointestinal disorders10/224/17
ABDOMINAL DISTENSIONGastrointestinal disorders6/226/17
DYSPNOEARespiratory, thoracic and mediastinal disorders1/226/17
ALOPECIASkin and subcutaneous tissue disorders7/226/17
DYSPNOEACardiac disorders1/226/17
FLATULENCEGastrointestinal disorders3/225/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)MetforminPlaceboTotal
Mean55 (39 to 75)57 (41 to 73)55.9 (39 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)MetforminPlaceboTotal
Female221840
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MetforminPlaceboTotal
American Indian or Alaska Native000
Asian549
Native Hawaiian or Other Pacific Islander000
Black or African American011
White171330
More than one race000
Unknown or Not Reported000
ECOG Performance Scale
ECOG Performance Scale(Participants)MetforminPlaceboTotal
ECOG 0-1201636
ECOG 2224
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)MetforminPlaceboTotal
Mean26.5 (18.8 to 42.4)26.6 (20.5 to 37.9)26.5 (18.8 to 42.4)
Receptor Status
Receptor Status(participants)MetforminPlaceboTotal
(Estrogen Receptor (ER)/Progesterone Receptor (PR) positive191534
ER/PR negative336
Human epidermal growth factor receptor 2 (HER2) status
Human epidermal growth factor receptor 2 (HER2) status(participants)MetforminPlaceboTotal
HER2 positive246
HER2 negative201434
Any adjuvant chemotherapy
Any adjuvant chemotherapy(participants)MetforminPlaceboTotal
Yes131225
No9615

5 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • London Regional Cancer Program
    London, Ontario, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1N9, Canada
  • Mount Sinai Hospital
    Toronto, Ontario M5G 1X5, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Windsor Regional Cancer Centre
    Windsor, Ontario N8W 2X3, Canada
09

References and documents

Publications

  • Pimentel I, Lohmann AE, Ennis M, Dowling RJO, Cescon D, Elser C, Potvin KR, Haq R, Hamm C, Chang MC, Stambolic V, Goodwin PJ. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast. 2019 Dec;48:17-23. doi: 10.1016/j.breast.2019.08.003. Epub 2019 Aug 22. PubMed 31472446 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Jul 2016, 58 months.

Results were first posted in Apr 2021, 4 years 9 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 58 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2011
First posted
Mar 8, 2011
StartActual
Aug 22, 2011
Primary completionActual
Jul 14, 2016
CompletionActual
Mar 26, 2018
Results first posted
Apr 14, 2021
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01310231
Lead sponsor
Ozmosis Research Inc.
Collaborators
Breast Cancer Research Foundation
Responsible party
Sponsor
First posted
Mar 8, 2011
Start date
Aug 22, 2011
Primary completion
Jul 14, 2016
Completion
Mar 26, 2018
Results posted
Apr 14, 2021
Last update
Apr 14, 2021

Study contacts

Pamela J Goodwin, MD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion